Can anti-IgE be used to treat allergy?

@article{Davis2004CanAB,
  title={Can anti-IgE be used to treat allergy?},
  author={F. Davis and L. A. Gossett and K. Pinkston and R. Liou and L. Sun and Y. Kim and N. Chang and T. Chang and K. Wagner and J. Bews and V. Brinkmann and H. Towbin and N. Subramanian and C. Heusser},
  journal={Springer Seminars in Immunopathology},
  year={2004},
  volume={15},
  pages={51-73}
}
Summary and conclusionA summary of the properties of CGP 51901 is shown in Table 3. On the basis of its binding to IgE and IgE-secreting cells and its activity in vitro and in vivo, CGP 51901 is expected to be able to decrease serum IgE by direct clearance of IgE and by reduction of the numbers and productivity of IgE-secreting cells. The end result of reduction of IgE in the circulation and on mast cells is expected to be the attenuation of IgE-mediated reactions and the improvement in allergy… Expand
View on Springer
ncbi.nlm.nih.gov
41 Citations
Background Citations
9
Methods Citations
1
Results Citations
1

41 Citations

Citation Type

Citation Type

Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
TLDR
Anti-IgE appears to provide a prophylactic and therapeutic option for moderate to severe cases of many allergic diseases and conditions in which IgE plays a significant role and has potential for use to combine with specific and rush immunotherapy for increased safety and efficacy. Expand
Anti-IgE as a mast cell-stabilizing therapeutic agent.
TLDR
This therapeutic anti-IgE represents a new class of mast cell-stabilizing agents, reducing FcepsilonRI density on mast cells and basophils and causing them to be insensitive to allergens, thus deflating the intracellular activation signal triggered by IgE-FcePSilonRI aggregation. Expand
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
TLDR
A pharmacokinetic-pharmacodynamic model incorporating omalizumab-IgE binding and feedback for control of IgE production indicates that omalIZumab reduces production of IgN, raising the possibility that indefinite treatment may not be required, only for perhaps a few years. Expand
Will Anti-IgE Therapy Compromise Normal
TLDR
The IgE-mediated immune mechanism seems to have a modest role in the protection of human subjects against the infection of parasitic worms since the defense function is handled by several redundant immune mechanisms. Expand
Effect of anti-IgE therapy in patients with peanut allergy.
TLDR
A 450-mg dose of TNX-901 significantly and substantially increased the threshold of sensitivity to peanut on oral food challenge from a level equal to approximately half a peanut to one equal to almost nine peanuts, an effect that should translate into protection against most unintended ingestions of peanuts. Expand
Development and characterization of a novel anti-IgE monoclonal antibody.
TLDR
The data showed that 7A5 could inhibit free IgE molecules to bind to receptors without affecting IgE already bound to cellular receptors, and was able to inhibit IgE-induced histamine release of basophilic leukemia cells. Expand
Inhibition of human airway sensitization by a novel monoclonal anti-IgE antibody, 17-9.
TLDR
It is concluded that allergen responses in sensitized human airways are dependent on IgE levels in the sensitizing serum while nonspecific (hyper)responsiveness depends on serum factors other than IgE. Expand
Anti-IgE Therapy
TLDR
Omalizumab, a recombinant humanized IgG1 antibody with a unique set of binding specificities toward human IgE, has been approved in the United States and Australia for treating adult and adolescent patients with moderate to severe asthma and for protecting against anaphylactic reactions to peanuts. Expand
Molecular aspects of allergy.
Atopic diseases such as asthma, rhinitis, eczema and food allergies have increased in most industrialised countries of the world during the last 20 years. The reasons for this increase are not known… Expand
Past, present, and future of anti‐IgE biologics
TLDR
The molecular properties of past and present anti‐IgE biologicals are highlighted and concepts that might improve treatment efficacy of future drug candidates are suggested. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Parasites and allergy: evidence for a ‘cause and effect’ relationship
  • R. Moqbel, D. Pritchard
  • Medicine
  • Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 1990
TLDR
The IgE/mast cell system almost certainly evolved to enhance protection rather than simply to mediate clinical allergic reactions against normally harmless substances to which man is constantly exposed. Expand
IL-4 requirements for the generation of secondary in vivo IgE responses.
TLDR
Evidence is provided that IL-4 is required for virgin B lymphocytes to develop into IgE-expressing cells, but is not required for B cells that express intrinsic membrane IgE to differentiate into Ig E-secreting cells in a T-dependent response. Expand
Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE.
  • S. Haba, A. Nisonoff
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1990
Inoculation of syngeneic IgE into 2- to 12-day-old mice results in prolonged synthesis of anti-IgE antibodies without further challenge. These anti-IgE antibodies may be largely responsible for the… Expand
Anti-human IgG causes basophil histamine release by acting on IgG-IgE complexes bound to IgE receptors.
TLDR
The ability of anti-human IgG antibodies to induce histamine release from human basophils is reexamined and it is concluded that anti-IgG-induced release occurs as a result of binding to IgG anti-iGE antibodies and cross-linking of the IgE receptors on basophil. Expand
Human IgE-binding factors.
TLDR
Several new findings are summarized regarding the cellular origin, structure and function of IgE-BFs/sCD23, a B-cell surface marker thought to be involved in the control of B- cell proliferation or differentiation. Expand
IgE-binding factors and regulation of the IgE antibody response.
  • K. Ishizaka
  • Biology, Medicine
  • Annual review of immunology
  • 1988
TLDR
If the same procedures would be effective for human T cells of allergic patients, it would be possible to generate antigen-specific suppressor T cells from their T cell population in vitro and to establish T cell hybridomas that produce allergen-specific GIF(TsF). Expand
New concepts of IgE regulation.
TLDR
It is demonstrated that in certain established immune situations the IgE response may become independent of IL-4, namely in the spontaneous in vitro IgE expression of cells from atopic individuals as well as in an in vitro antigen-induced secondary IgEresponse of spleen cells derived from previously immunized mice. Expand
Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1.
TLDR
Results indicate an important physiologic role for BSF-1 in the generation of IgE antibody responses and suggest means for limiting the production of antibodies responsible for allergic reactions without inhibiting protective antibody responses. Expand
Induction of an auto‐anti‐IgE response in rats. I. Effects on serum IgE concentrations
With a view to specifically suppressing the IgE isotype, rats of high (BN) and low (PVG. RT1u) IgE‐responding phenotypes were immunized with a highly purified rat IgE myeloma (IR2) in an attempt to… Expand
Lymphokine control of in vivo immunoglobulin isotype selection.
TLDR
There is no direct evidence that IL-5 contributes to the generation of in vivo antibody responses, but two general conclusions may also be drawn. Expand
...
1
2
3
4
5
...